Europe — EMA
Nephromag (Buffered Phosphate Solution | Mertiatide)
GNH USA supplies Nephromag (Mertiatide), a buffered phosphate solution for correcting phosphate balance and electrolyte disturbances.
Request sourcing
What is Buffered Phosphate Solution | Mertiatide?
Mertiatide, the active ingredient in Nephromag, is a buffered phosphate solution presented as a solution for injection for intravenous use. It is employed to support phosphate balance in patients requiring electrolyte management.
GNH USA supplies Nephromag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.
What is Buffered Phosphate Solution | Mertiatide used for?
Nephromag, an intravenous buffered phosphate solution, is used to manage phosphate homeostasis and related electrolyte disturbances.
Acute hypophosphatemia: restores serum phosphate levels in patients with low phosphate. Renal replacement therapy: provides phosphate supplementation during dialysis. Post‑operative care: supports electrolyte balance after major surgery.
What are the side effects of Buffered Phosphate Solution | Mertiatide?
Nephromag may be associated with several adverse reactions following intravenous administration.
Common Side Effects: - Transient hyperphosphatemia - Hypocalcemia - Local infusion site irritation - Nausea - Headache
Serious or Rare Side Effects: - Severe hyperphosphatemia leading to calcium‑phosphate precipitation - Allergic reaction (anaphylaxis) - Metabolic acidosis - Exacerbation of renal dysfunction - Severe electrolyte imbalance
What precautions apply to Buffered Phosphate Solution | Mertiatide?
Prior to using Nephromag, clinicians should consider specific safety measures.
Assess serum phosphate and calcium levels before administration: ensure baseline values are within therapeutic range. Monitor renal function during therapy: adjust dosing in patients with impaired kidney function. Adjust dose in renal impairment: reduce infusion rate as needed. Avoid concurrent calcium‑containing IV solutions: prevent precipitation risk. Use with caution in hyperparathyroidism: altered calcium‑phosphate metabolism may increase complications. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.
What does Buffered Phosphate Solution | Mertiatide interact with?
Nephromag can interact with other agents that affect phosphate or calcium balance.
Major Interactions (Avoid): - Calcium‑containing IV solutions: may precipitate calcium phosphate. - Iron dextran: can bind phosphate reducing efficacy. - Aluminum‑containing antacids: increase phosphate absorption leading to toxicity.
Moderate Interactions (Monitor Closely): - Loop diuretics: may increase phosphate loss. - ACE inhibitors: affect renal phosphate handling. - Vitamin D analogues: alter calcium‑phosphate balance.
